As surgical collaborators in this study, we think that it shows that the most appropriate approach to patients with multivessel disease is apparent from this and the previous report from the ARTS trial. This could not have been expressed better than in the last sentence in the Results section, which should have been moved to the Conclusions section of the report.
nificant periprocedural complications associated with the laser technique (including pericardial tamponade or effusions in 7.0% of patients, and ventricular arrhythmias necessitating cardioversion in 5.6%), without enduring improvement in symptoms or exercise tolerance (2) . Perin and Colleagues bemoan the lack of 12-month follow-up in our study. Unfortunately, such data was requested and not supplied by the sponsor. Moreover, the weak trend in our study toward less angina in PMR-treated patients at 3 months was diminishing at 6 months, making it doubtful that 12-month follow-up would have revealed significant symptomatic improvement. Their second comment reiterates our acknowledged limitation that the rate of paired exercise testing was lower than anticipated. However, as statistically discussed in the report (2) , given the observed mean difference in exercise tolerance of only 17 s between groups, it is highly unlikely that a greater number of patients would have altered our conclusions.
Third, Perin et al. question the fact that our study was adequately blinded, which may have contributed to the negative findings. This is counterintuitive; lack of blinding would have favored the active treatment group, making the trial more positive. Moreover, it is unclear how blinded the BELIEF study was; the laser in the sham group was connected to a "lead box," which likely precluded the characteristic visual and acoustic signals when the laser was fired. This small (only 82 randomized patients) though well-designed study also showed no difference in exercise tolerance between PMR and placebo groups, and incremental improvement in angina by Ն1 class at 12 months in only 24% of treated patients (n ϭ 10), which may have been due to chance given the small sample size (3). We therefore cannot agree with their statement that BELIEF has "effectively addressed" the placebo question, given the results of the much larger, blinded DIRECT trial (4) .
Finally, although we agree with Perin and Co-workers that the three holmium yttrium-aluminium-garnet (YAG) laser systems subjected to clinical trials are different, and stated so in the last paragraph of our report (2), we strongly disagree with their statement that "Based on the negative outcome for the DIRECT trial utilizing the DMR system, it is clear that fiberoptic penetration into the myocardium and significant channel formation, as with PMR, are essential to achieving clinical benefit." Evaluating whether the different modes of energy delivery or myocardial penetration has anything to do with clinical efficacy would require a comparative study between the two systems, or absent this, at least a positive adequately sized multicenter blinded study of PMR using the CardioGenesis system.
We suggest that rather than arguing the merits of the currently completed trials, all of which are flawed to some degree, Perin et al. focus on lobbying for an adequately powered, appropriately blinded clinical trial to once and for all either prove the safety and efficacy of PMR, or, alternatively, demonstrate its futility. Otherwise, it is doubtful that this once promising approach will ever become widely accepted by the clinical community.
Stented Angioplasty or Coronary Artery Bypass Graft Surgery for Multivessel Disease?
The recent report from the ARTS trial focuses on the effect of completeness of revascularization on the outcome within each cohort (1). In the previous report from the trial, on the basis of a small difference in the cost of treatment during the first year in favor of stented angioplasty, but in the absence of difference in the rate of major complications and with a repeat revascularization rate more than five times greater among the stented patients, the investigators concluded that there is no advantage to surgery over angioplasty in patients with multivessel disease (2). Now we learn that when the interventional cardiologists estimated that, using stented angioplasty, they could achieve a degree of revascularization equal to surgical revascularization, they were, in fact, able to provide this degree of completeness to a substantially lower number of patients (70.5% vs. 84.1%). The significantly better revascularization in the surgical group was accomplished without increased incidence of stroke, myocardial infarction, or death. Patients in this trial, who were randomized to stented angioplasty and received incomplete revascularization (30%), could have much better freedom from death and other major complications, reducing the need for subsequent bypass surgery from 10% to only 0.2% to 1.1%, with only minimal effect of completeness of revascularization. However, the investigators elected to emphasize the effect of complete revascularization; the fact that even with complete revascularization, the stented patients had a one-year event-free survival much inferior to their surgical counterparts does not appear, as it should, in the conclusions of their report.
Another unanswered question is what happened to the left ventricle (LV) using an approach that resulted in the need for repeat revascularization in every fifth patient. Were all the ischemic episodes indicating the need for further revascularization procedures free of irreversible myocardial damage? And was the subsequent procedure, carrying a 5% to 6% infarction rate in the index procedure, free of damage the second time? Has LV function remained unchanged in both groups?
The researchers conclude that the effectiveness and costeffectiveness of angioplasty can be further enhanced by careful selection of patients. The cohort assigned to this study consisted of lesser proportion of patients with totally obstructed vessels, small or multilesion vessels, and at least two lesions in arteries Ͼ2.75 mm, leading to two different territories. Such patients are almost ideal candidates for angioplasty. Careful selection of candidates from among these patients will further limit the application of the study results to the entire population of patients with multivessel disease.
REPLY
We have read with interest the comments of Doctors Elami and Merin relating to our study "The Effect of Completeness of Revascularization on Event-free Survival" (1). It is remarkable that the title of their communication is "Stented Angioplasty or Coronary artery Bypass Graft Surgery for Multivessel Disease?" Indeed, most of their comments apply to the general results of the ARTS trial as published by Serruys et al. (2) . The reasoning behind our study was threefold. First, both angioplasty and surgery have a substantial number of patients left with anatomical incomplete revascularization. This means that interventional cardiologists should seek optimal patient selection to achieve complete revascularization, as this leads to a 7% higher event-free survival at one year. Surgeons also could do better, as they achieve complete revascularization in only five out of six patients, albeit without a significant difference in outcome between both groups at one year.
Second, even with incomplete percutaneous revascularization, the number of irreversible events was not higher than for the other three subgroups, as can be learned from Table 3 of our report. Thus, the higher number of revascularizations in the (PCI) patients did not lead to a higher number of infarctions, although left ventricular function has not routinely been measured at follow-up. This means that within the selection criteria of the ARTS trial, the patient and the doctor could opt for intentionally incomplete percutaneous revascularization without endangering the patient's life expectancy and without infarcts and cerebrovascular accidents. This still appeals to numerous patients as an agreeable alternative to surgery, notwithstanding the advances that have been made in surgical techniques. At one year, 98% of PCI patients with complete revascularization were free from coronary artery bypass graft surgery (CABG) compared to only 90% of the incompletely percutaneously revascularized patients.
Third, in European countries the portion of PCI in the total number of coronary revascularizations is between 40% and 70% (3).
Nevertheless, the vast majority ot these percutaneous revascularizations are still performed in patients with single-vessel disease (e.g., 86% in The Netherlands; database BHN, first quarter 2002). The ARTS trial was developed to explore the outcome of multivessel-stented PCI. In retrospect, we tried to investigate whether incomplete and complete revascularization had the same effect on percutaneously and surgically treated patients. We found that patients incompletely revascularized with PCI needed more reinterventions. To enhance the outcome of multivessel PCI, we concluded that complete revascularization is a good guarantee for survival without CABG, with a 13% re-PCI rate. If the promises of rapamycin-coated stents are confirmed (4), and restenoses are prevented, complete PCI revascularization can compete with surgery, not only in preventing surgery, but also making it a one-time procedure like surgery. But even without restenosis, careful selection of patients to achieve complete revascularization is a prerequisite for event-free survival after PCI. 
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